We provide you with 20 years of free, institutional-grade data for SCYX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SCYX. Explore the full financial landscape of SCYX stock.
| Reported Date | CIK | Ticker | Type |
|---|
SCYNEXIS, Inc(NASDAQ:SCYX) 
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, i...
Website: http://www.scynexis.com
Full Time Employees: 27
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
The information provided in this report about SCYX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.